Drug updated on 9/4/2024
| Dosage Form | Injection (intravenous; 1 mg/mL, 2 mg/2 mL [1 mg/mL] in single-dose vials, 30 mg/30 mL [1 mg/mL] in single-patient-use vial) |
| Drug Class | Opioid agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Latest News
Summary
- Olinvyk (oliceridine) is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- The systematic review and meta-analysis indicated that oliceridine had a significantly higher response rate compared to placebo, with effectiveness similar to morphine in terms of analgesic effects.
- Oliceridine was effective in the general postoperative pain population, with no specific subgroups or population types highlighted regarding effectiveness outcomes.
- The incidence of adverse events, specifically nausea and vomiting, was significantly higher with oliceridine compared to placebo.
- Oliceridine had a significantly lower incidence of respiratory safety events compared to morphine, suggesting a superior overall safety profile in this aspect, although it also resulted in more frequent nausea and vomiting events than morphine.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Olinvyk (oliceridine) Prescribing Information. | 2021 | Trevena, Inc., Chesterbrook, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and safety of oliceridine treatment in patients with postoperative pain: a systematic review and meta-analysis of randomized controlled trials. | 2023 | Expert Review of Clinical Pharmacology |
| Oliceridine for the management of moderate to severe acute postoperative pain: a narrative review. | 2023 | Drug Design, Development and Therapy |